All In Biotech

Drug Trial Radar · NCT02297438

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF PREVIOUSLY UNTREATED ASIAN POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) ADVANCED BREAST CANCER

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

340

Actual

Start

Mar 23, 2015

Primary completion

Aug 31, 2020

Study completion Feb 24, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.

Conditions

  • Breast Neoplasms

Interventions

  • PalbociclibDrug

    Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

  • LetrozoleDrug

    Letrozole, 2.5mg, orally once daily (continuously)

  • PlaceboDrug

    Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

  • LetrozoleDrug

    Letrozole, 2.5mg, orally once daily (continuously)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion DateTime frame: Randomization up to 65 months

Locations

54 sites in 5 countries. Site status is shown where the registry gives one.

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing, China

  • 307 Hospital of PLA

    Beijing, China

  • Beijing Cancer Hospital

    Beijing, China

  • Peking University Third Hospital/Department of Oncology

    Beijing, China

  • Chinese PLA General Hospital/Oncology

    Beijing, China

  • Oncology Department, the Second Affiliated Hospital of Third Military Medical University, PLA

    Chongqing, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Fujian Medical University Union Hospital/Medical Oncology Department

    Fuzhou, Fujian, China

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China

  • Zhongshan Ophthalmic Center,Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • Breast Tumor Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital/Oncology Department

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Hunan Provincial Tumor Hospital/Breast Internal Medicine Department

    Changsha, Hunan, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Jilin Provincial Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of China Medical University/Oncology Department

    Shenyang, Liaoning, China

  • Liaoning Province Cancer Hospital

    Shenyang, Liaoning, China

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Cancer Hospital/Breast cancer department

    Tianjin, Tianjin Municipality, China

  • The Tumor Hospital of Yunnan Province

    Kunming, Yunnan, China

  • The First Affiliated Hospital of College of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • Department of Clinical Oncology

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Raffles Cancer Centre

    Singapore, Singapore

  • Parkway Cancer Centre

    Singapore, Singapore

  • Tan Tock Seng Hospital

    Singapore, Singapore

  • Tan Tock Seng Hospital

    Singapore, Singapore

  • China Medical University Hospital

    Taichung, Taiwan

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.